Roche has tapped Simcere Zaiming for a new T cell engager that could have broad application in B cell–mediated diseases including lymphoma and autoimmune conditions.

Original title: “Roche finds another oncology gem in Asia with $1.5B B cell disease partnership”

unusual sequential development of multiple sclerosis thymoma myasthenia and lymphoma in the same patient

Original title: “Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.”

Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. Chimeric antigen receptor (CAR)-T cell therapy, which reprograms an individual's immune cells to seek out and destroy certain cancer cells, has revolutionized treatment for blood cancers such as lymphoma. But in some patients, the treatment can cause serious side effects. New research led by investigators at the Mass General Brigham Cancer Institute, the Broad Institute of MIT and Harvard, and Dana-Farber Cancer Institute has shown that patients' inherited genetic makeup can influence whether they benefit from CAR-T cell therapy or experience toxicity from the treatment. These findings have important implications for understanding how CAR-T cells behave in patients since each CAR-T cell product is unique to the person from whom it is manufactured, unlike all prior forms of therapy, which are identical across patients." Mark B. Leick, MD, lead author, oncologist, Mass General Brigham Cancer Institute For the study, Leick and his colleagues sequenced the entire genomes of more than 200 patients with aggressive lymphoma from two major clinical trials of CAR-T cell therapy. In one of the trials, patients with T cells with variants that silenced the STXBP2 gene tended to experience toxicity related to CAR-T cell therapy. In both clinical trials, variants in the ADAMTSL3 gene correlated with protection from treatment-related toxicity, and variants in the PTPN22 gene were strongly associated with enhanced CAR T-cell expansion, which correlates with effective therapy.

Original title: “Inherited genetics can influence safety and success of CAR-T cell therapy”

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.

Original title: “Legend surges on early data for ‘in vivo’ lymphoma cell therapy”

rare solid tumor frequently misdiagnosed as lymphoma primary colonic epstein barr virus positive inflammatory follicular dendritic cell sarcoma

Original title: “A rare solid tumor frequently misdiagnosed as lymphoma: primary colonic Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma.”

primary lymphoma of the acromion presenting with isolated shoulder pain

Original title: “Primary lymphoma of the acromion presenting with isolated shoulder pain.”

FDA announces cancer drug trials by AstraZeneca and Amgen will be monitored in real time, a test of how to shorten time interval between trial phases. Monitoring trials in real time may help shorten the time interval between trial phases. The agency also asked the public to weigh in on a potential pilot program to work with companies that use AI to enhance safety monitoring and medication dose selections, identify safety signals, and improve patient recruitment in clinical trials. ... AstraZeneca is conducting a Phase 2 trial of its combination therapy for patients with an aggressive form of lymphoma. The trial will take place at the University of Texas MD Anderson Cancer Center and the University of Pennsylvania. Amgen is conducting a Phase 1b trial of its treatment for small cell lung carcinoma. WASHINGTON — The Food and Drug Administration on Tuesday announced efforts to make clinical trials more efficient, starting by reviewing data in real time from trials conducted by AstraZeneca and Amgen.

Original title: “FDA testing speedier drug development with real-time clinical trials | STAT”

Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.

Original title: “Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma”

Pivotal findings for the off-the-shelf cell therapy surpassed William Blair’s expectations and sent Allogene Therapeutics’ stock up more than 50% in pre-market trading Monday morning.

Original title: “Allogene stock sails after CAR T clears residual lymphoma in early data cut”

swelling of the foreskin and glans penis as a sign of lymphoma

Original title: “[Swelling of the foreskin and glans penis as a sign of lymphoma].”